Entera Bio ENTX 深 沪
交易中 10-06 10:35:13 美东时间
2.535
-0.085
-3.24%
华盛通- 最 高3.5595
- 今 开2.66
- 成交量 14.17万股
- 最 低 2.535
- 昨 收 2.62
- 总市值 7.30万
- 52周最高 4.20
- 市盈率 静 --
- 换手率 491.70%
- 52周最低 0.91
- 委 比 -6.85%
- 总股本 2.88万
- 历史最高 10.16
- 量 比 2.11
- 振 幅 39.10%
- 历史最低 0.47
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cantor Fitzgerald Initiates Coverage On Entera Bio with Overweight Rating
Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Entera Bio (NASDAQ:ENTX) with a Overweight rating.
09-22 18:36
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings
Dow Jones up 0.80% to 52,361.92, NASDAQ up 0.23% to 25,024.65, S&P 500 up 0.28% to 7,432.59. Communication services up 2.5%, energy down 1.84%.
07-27 22:21
Phreesia, Progress Software And 3 Stocks To Watch Heading Into Monday
U.S. stock futures up, focus on quarterly earnings of Americas Gold and Silver, ARKO Petroleum, Entera Bio, Phreesia, and Progress Software.
03-30 15:29
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Entrada Therapeutics secures EU authorization for ELEVATE-45-201, a Phase 1/2 study of ENTR-601-45 for Duchenne muscular dystrophy patients amenable to exon 45 skipping. The study aims to assess safety, tolerability, and efficacy, with initiation planned for Q3 2025. ENTR-601-45 is an exon-skipping therapy designed to restore dystrophin production, addressing a significant unmet need in this DMD subpopulation.
2025-05-28 11:00
